Oruka Therapeutics, Inc. (ORKA)

Oruka Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Year Ending	Current	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Market Capitalization	835	24	34	31	37	9
Market Cap Growth	89.94%	-28.27%	10.23%	-17.11%	310.61%	96.04%
Enterprise Value	849	-13	-8	-22	-11	1
PE Ratio	-	-4.59	-3.44	-1.60	-3.84	-1.66
PB Ratio	1.71	0.66	0.82	0.61	0.80	1.20
P/FCF Ratio	-8.07	-4.89	-3.13	-1.65	-4.83	-1.89
P/OCF Ratio	-8.07	-4.89	-3.13	-1.65	-4.84	-1.90
EV/EBITDA Ratio	-3.13	2.43	0.82	1.14	1.17	-0.13
EV/EBIT Ratio	-3.09	2.38	0.81	1.14	1.16	-0.13
EV/FCF Ratio	-3.23	2.54	0.73	1.17	1.46	-0.15
Debt / Equity Ratio	-	0.01	0.01	0.01	0.01	-
Debt / EBITDA Ratio	-	-0.04	-0.03	-0.02	-0.04	-
Debt / FCF Ratio	-	-0.04	-0.03	-0.02	-0.05	-
Quick Ratio	26.19	58.76	37.50	15.25	14.02	9.03
Current Ratio	26.61	59.01	37.72	15.56	14.28	9.16
Interest Coverage	-	-	-	-	-1082.00	-806.00
Return on Equity (ROE)	-20.20%	-13.80%	-22.40%	-32.90%	-34.30%	-66.60%
Return on Assets (ROA)	-19.50%	-13.30%	-21.20%	-31.00%	-32.10%	-58.50%
Return on Capital (ROIC)	-28.03%	-19.60%	-25.26%	-37.60%	-20.81%	-76.40%
Earnings Yield	-12.96%	-21.79%	-29.06%	-62.37%	-26.05%	-60.22%
FCF Yield	-12.40%	-20.47%	-31.96%	-60.70%	-20.72%	-52.78%
Buyback Yield / Dilution	-0.67%	-0.04%	-3.64%	-195.18%	-256.50%	-71.72%
Total Shareholder Return	-0.67%	-0.04%	-3.64%	-195.18%	-256.50%	-71.72%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).